Bausch Health Companies Inc.

Bausch Health Companies Inc. develops, manufactures, and markets specialty pharmaceuticals, over-the-counter products, and medical devices. The company focuses primarily on therapeutic areas such as gastroenterology, hepatology, neurology, dermatology, and eye health. Its business operates across five reportable segments: Salix, International, Solta Medical, Diversified, and Bausch + Lomb. Salix handles U.S. gastrointestinal treatments, while Solta Medical provides aesthetic medical systems. The International segment manages pharmaceutical and consumer healthcare sales outside the United States. Diversified covers U.S. neurology, dermatology, dentistry, and generic medications, and Bausch + Lomb delivers vision care, surgical platforms, and ophthalmic pharmaceuticals to patients and healthcare providers.

The enterprise maintains an extensive global presence, marketing approximately 1,000 products directly or indirectly across roughly 90 countries. Its operations include dedicated research, development, and quality assurance personnel active across 25 research and development facilities worldwide. The company's headquarters are not stated in the provided text.

Summary of the business section of Bausch Health Companies's latest annual report, written by StockData.

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

“As of December 31, 2025, we had approximately 20,300 employees, of which approximately 13,000 were Bausch + Lomb employees.”